Kainos Laboratories

Kainos Laboratories EBITDA

Delisted

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kainos Laboratories (4556.T) as of Oct 29, 2026 is 883.19 M JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 936.45 M JPY — a change of -5.69% (lower).

EBITDA

883.19 MJPY

YoY

-5.69%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kainos Laboratories is 2025 883.19 M JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kainos Laboratories was 2024 936.45 M JPY. It decreases by -5.69% lower compared to the previous year.

The Kainos Laboratories EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
501.29 M JPY
Jan 1, 2019
625.61 M JPY
Jan 1, 2020
665.03 M JPY
Jan 1, 2021
694.87 M JPY
Jan 1, 2022
803.80 M JPY
Jan 1, 2023
883.40 M JPY
Jan 1, 2024
936.45 M JPY
Jan 1, 2025
883.19 M JPY
The Kainos Laboratories EBITDA history
YEAREBITDAYoY
883.19 MJPY-5.69%
936.45 MJPY+6.00%
883.40 MJPY+9.90%
803.80 MJPY+15.68%
694.87 MJPY+4.49%
665.03 MJPY+6.30%
625.61 MJPY+24.80%
501.29 MJPY-4.67%
525.83 MJPY+5.50%
498.43 MJPY+6.04%
470.04 MJPY+22.73%
383.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kainos Laboratories Stock analysis

What does Kainos Laboratories do? Kainos Laboratories Inc develops and manufactures pharmaceuticals, diagnostic reagents, and related chemical products for distribution and import/export. The company sells its products to healthcare providers, hospitals, and medical institutions within Japan and internationally. Its core offerings include prescription medications, diagnostic tools, and chemical compounds used in medical research and treatment. The business model relies on direct sales to medical facilities and global trade of its pharmaceutical and diagnostic solutions. Kainos Laboratories Inc focuses on the Japanese market with its headquarters in Bunkyo-Ku, Tokyo-To, while also engaging in international import/export activities. The company's revenue streams come from the sale of pharmaceuticals, diagnostic reagents, and chemical products to healthcare professionals and institutions. Its product portfolio targets medical practitioners and research organizations requiring specialized diagnostic and therapeutic solutions. The company operates with 144 full-time employees dedicated to the development, manufacturing, and distribution of its products. Kainos Laboratories Inc generates income through the commercialization of its pharmaceuticals and diagnostic reagents, serving both domestic and global clients in the healthcare sector. Sales are driven by demand for medical treatments and diagnostic tools in clinical and research settings. Kainos Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kainos Laboratories stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kainos Laboratories is 883.19 M JPY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kainos Laboratories changed from 936.45 M JPY to 883.19 M JPY, representing a -5.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Kainos Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Kainos Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Kainos Laboratories

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Kainos Laboratories